Biphenyl dimethyl dicarboxylate.
Treatment of chronic and persistent hepatitis that is associated with a high ALT level or drug-induced high transaminase level.
Adults: Usual dosage is 1-2 tablets 3 times daily. Dosage can be increased by the direction of a physician.
Bidica should be used with caution in patients with chronic active hepatitis and cirrhosis.
In patients with elevated ALT level during administration of Bidica, ALT can increase after the end of administration, but it can be improved through re-administration of Bidica.
Use in pregnancy & lactation: Bidica should not be administered in pregnant and nursing mother.
Use in children: Bidica should be administered to young child in reduced dosage.
Use in the elderly: Usually administered in reduced quantity because of their depreciated physiology.
Bidica should not be administered in pregnant and nursing mother.
If thirst, nausea, rash occurs, the patient should administer Bidica with an anti-hypersensitivity agent.
If temporary jaundice occurs, the patient should discontinue the administration or administer Bidica with treatment for jaundice.
Nausea and abdominal distention can occur rarely but the symptoms are lost soon.
When Bidica is administered concomitantly with inosine, relapsed ALT's rise can improve.
Store below 30°C. Protect from sunlight and humidity.
Shelf-Life: 3 years.
A05BA - Liver therapy ; Used in liver therapy.
Tab (oblong and white) 25 mg x 12 x 10's.